Myeloproliferative diseases (CML excluded)

DOID MESH PheWeb

MYELOPROF_NONCML

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions

not CML

321116

Filter registries None

Check pre-conditions, main-only, mode, ICD version None

Check minimum number of events None

Include endpoints

POLYCYTVERA

CHRONMYELOPRO

THROMBOCYTAEMIA

MYELOFIBROSIS

1356

MYELOPROF_NONCML

Extra metadata

First used in FinnGen datafreeze DF2, additional

Similar endpoints

↥

List of similar endpoints to Myeloproliferative diseases (CML excluded) based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Myelofibrosis

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	1321	694	627
Unadjusted prevalence (%)	0.43	0.40	0.46
Mean age at first event (years)	61.02	60.17	61.97

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.04	3.64 [2.03, 6.52]	1.4e-5	216
15 years	0.01	2.13 [1.28, 3.52]	3.4e-3	105
5 years	0.00	3.32 [2.29, 4.80]	1.9e-10	59
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: MYELOPROF_NONCML – Myeloproliferative diseases (CML excluded)
GWS hits: 8

Survival analyses between endpoints

↥

Plot

before Myeloproliferative diseases (CML excluded)
after Myeloproliferative diseases (CML excluded)

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Myeloproliferative diseases (CML excluded)

↥